A small study testing the pharmacodynamic effects of several antiplatelet agents suggests that tirofiban (Aggrastat; Medicure), a glycoprotein IIb/IIIa inhibitor, may provide “more potent and ...
Nov. 14, 2005 — The U.S. Food and Drug Administration (FDA) has approved a real-time cardiopulmonary resuscitation monitoring and feedback device to assist responders in providing appropriate ...
Widely prescribed blood thinners such as COX-1 inhibitor aspirin and P2Y12 antagonist Plavix have a common problem: By decreasing platelet aggregation, they also increase the risk of uncontrolled ...
A recently recognized drug-drug interaction between opioids and P2Y12 inhibitors may have clinical implications for patients with ACS. Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results